Refractory Dermatomyositis Treated With Anifrolumab: Clinical Response and Dynamics of Type-I Interferon Signature.
M E Gimeno-Ribes, A Mensa-Vilaro, J I Aróstegui et al.
✦ AI-curated · Sources linked
Case in brief
A patient with refractory dermatomyositis (DM) was treated with anifrolumab, a monoclonal antibody targeting the type-I interferon receptor. The treatment resulted in an almost complete cutaneous response. Longitudinal analysis showed a decrease in the type-I interferon signature during therapy, suggesting a link between this pathway and disease activity in refractory cases.
Diagnostic / clinical pearl
Clinicians should consider anifrolumab as a potential treatment for refractory dermatomyositis, particularly in cases where type-I interferon signaling is implicated.
Why it matters
The findings support the role of type-I interferon in the pathogenesis of refractory DM and highlight its signature as a possible biomarker for monitoring treatment response.